Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Ensysce Biosciences completed the acquisition of Cy Biopharma, adding clinical-stage asset CY200 for Complex Regional Pain Syndrome which holds FDA Orphan Drug Designation, along with $17.1 million in target cash. The transaction is backed by up to $77 million in total financing, including $21.5 million from an initial private placement close led by Ally Bridge Group and an additional $38.6 million contingent on clinical trial milestones.
Key figures
- Ownership legacy pct
- 7.57
- Ownership target pct
- 74.94
- Ownership investors pct
- 17.49
- Target cash brought usd
- 17100000
- Post deal equity value usd
- 122900000
- Financing initial close usd
- 21500000
- Preferred price initial usd
- 321.79
- Financing total potential usd
- 77000000
- Preferred price milestone usd
- 402.24
- Financing milestone tranche usd
- 38600000
- Preferred shares issued to target
- 282122
- Preferred shares issued to investors
- 120260
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.